Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Revisions Proposed to Re-pricing Rule, Adjustment Based on Average Overseas Prices
August 8, 2011
- US FDA Issues Refusal to File Letter for Eisai's Perampanel
August 8, 2011
- “Dispensing Point”System Contributing to Higher Average Price per Prescription: GROWELL
August 8, 2011
- Proemend, Teribone Recommended for Approval
August 8, 2011
- Application for Zonegran Monotherapy for Epilepsy Accepted in Europe: Eisai
August 8, 2011
- JAS to Assess Risk Factors Based on Absolute Risk in Its Revised GLs for Prevention of AD
August 8, 2011
- Recommendation for Approval Withheld for Avastin for Breast Cancer
August 8, 2011
- SUEVEY
August 8, 2011
- Pregabalin to Be Recommended as 1st-line Drug in New GLs for Peripheral Neuropathic Pain
August 8, 2011
- Takeda Resubmits NDA for DPP-4 Inhibitor in the US
August 8, 2011
- Takara Bio Announces TCR Gene Therapy Collaboration in China
August 8, 2011
- MIC to Test Electronic Prescribing System
August 8, 2011
- Korosho's New GLs Call For Use of IT to Distribute Safety Info.
August 8, 2011
- Takeda to Start Multinational PIII Trial for TAK-875 in FY2011
August 8, 2011
- R&D Spending Fell, Discontinued Clinical Trials Increased in 2010: Thomson Reuters
August 8, 2011
- Kyowa Kirin Files for PD Treatment KW-6500 in Japan
August 8, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…